Target Name: NUP188
NCBI ID: G23511
Other Name(s): Nucleoporin 188 | nucleoporin 188kDa | NU188_HUMAN | Nucleoporin 188kDa | Nucleoporin NUP188 | nucleoporin NUP188 homolog | KIAA0169 | hNup188 | SANDSTEF | nucleoporin 188

Nucleoporin 188: A Promising Cancer Treatment and Biomarker

Nucleoporin 188 (NUP188) is a drug target and a biomarker that is being studied for its potential utility in cancer treatment. Nucleoporin 188 is a small molecule inhibitor of the nucleoporin gene, which encodes a protein called NUPORIN. This protein plays a critical role in cell division and is often expressed in high levels in cancer cells. By inhibiting the activity of NUPORIN, Nucleoporin 188 is thought to disrupt the ability of cancer cells to divide and grow.

One of the key advantages of Nucleoporin 188 is its ability to selectively target cancer cells, rather than healthy cells. This is because Nucleoporin 188 is designed to bind specifically to the NUPORIN protein, which is only expressed in high levels in cancer cells. By selectively targeting cancer cells, Nucleoporin 188 is able to reduce the risk of unintended side effects that may be associated with traditional cancer treatments.

Another potential advantage of Nucleoporin 188 is its ability to inhibit the growth of cancer cells in a dose-dependent manner. This means that the more Nucleoporin 188 is administered to cancer cells, the more effective it is at reducing their growth. This could make Nucleoporin 188 an effective treatment option for cancer patients who are experiencing rapid growth or who have not responded to traditional treatments.

In addition to its potential as a cancer treatment, Nucleoporin 188 is also being studied as a potential biomarker. This is because its ability to inhibit the growth of cancer cells can be used as a marker for the effectiveness of Nucleoporin 188. By measuring the growth of cancer cells before and after treatment with Nucleoporin 188, researchers can determine the drug's effectiveness and monitor its impact on cancer cells over time.

Overall, Nucleoporin 188 is a promising drug target and biomarker for cancer treatment. Its ability to selectively target cancer cells and inhibit their growth make it an attractive option for cancer treatments that are effective and safe. Further research is needed to determine the full potential of Nucleoporin 188 as a cancer treatment and to develop it as a reliable biomarker for cancer patients.

Protein Name: Nucleoporin 188

Functions: Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope (Probable). Required for proper protein transport into the nucleus (PubMed:32275884)

More Common Targets

NUP205 | NUP210 | NUP210L | NUP210P1 | NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2 | OAZ3 | OBI1 | OBI1-AS1 | OBP2A | OBP2B | OBSCN | OBSCN-AS1 | OBSL1 | OC90 | OCA2 | OCEL1 | OCIAD1 | OCIAD2 | OCLM | OCLN | OCLNP1 | OCM | OCM2 | OCRL | OCSTAMP | ODAD1 | ODAD2 | ODAD3 | ODAD4 | ODAM | ODAPH